Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BNTA is a potent extracellular matrix (ECM) modulator. In a rat model of arthritis, BNTA modulates arthritis by promoting the synthesis of cartilage structural molecules on chondrocytes through the induction of superoxide dismutase 3 (SOD3) and regulating chondrogenesis through superoxide anion elimination.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 84.00 | |
5 mg | In stock | $ 198.00 | |
10 mg | In stock | $ 328.00 | |
25 mg | In stock | $ 637.00 | |
50 mg | In stock | $ 892.00 | |
100 mg | In stock | $ 1,220.00 | |
500 mg | In stock | $ 2,450.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 198.00 |
Description | BNTA is a potent extracellular matrix (ECM) modulator. In a rat model of arthritis, BNTA modulates arthritis by promoting the synthesis of cartilage structural molecules on chondrocytes through the induction of superoxide dismutase 3 (SOD3) and regulating chondrogenesis through superoxide anion elimination. |
In vitro |
BNTA (0.01-10 μM; 1-7 days) exhibits no reduction in cell viability for human osteoarthritis chondrocytes and primary chondrocytes isolated from rats.[1] BNTA (0.1 μM; 2 days) induces a significant elevation in SOX9 protein expression. Notably, BNTA markedly enhances the protein levels of COL2A1 and SOX9 in rat osteoarthritis (OA) chondrocytes induced by IL1β.[1] BNTA (0.01-10 μM; 6 hours) enhances the expression levels of extracellular matrix (ECM)-related genes, including COL2A1, ACAN, proteoglycan 4 (PRG4), and SRY-box 9 (SOX9) in human osteoarthritis (OA) chondrocytes. In IL1β-induced rat OA chondrocytes, BNTA elevates Col2a1, Acan, Prg4, and Sox9 mRNA levels, with the most significant effects observed around 0.1 μM.[1] BNTA (10 μM; 5 days) increases proteoglycan staining in ATDC5 cells.[1] BNTA (0.01-1 μM; 2 or 3 weeks) enhances anabolism and inhibits inflammatory response in osteoarthritis cartilage explants.[1] |
In vivo | BNTA (0.015-1.5 mg/kg; intra-articular injection; twice a week for 4 and 8 weeks; Male SD rats ) attenuated post-traumatic osteoarthritis development after intra-articular injection well tolerated and could attenuate OA progression developed after anterior cruciate ligament transection (ACLT) in rats.[1] |
Molecular Weight | 456.76 |
Formula | C17H11BrClNO3S2 |
CAS No. | 685119-25-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 80 mg/mL (175.15 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
BNTA 685119-25-9 Immunology/Inflammation Metabolism NF-Κb Reactive Oxygen Species inhibitor inhibit